BSX vs EW
Boston Scientific and Edwards Lifesciences, both Healthcare
Boston Scientific is the larger company at $67B against $50B. On trailing earnings BSX is the cheaper of the two at a P/E of 19.5 against 52.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +15% against -53% for BSX. Ryufin's sector-relative Smart Score puts EW ahead, 7/10 against 6/10.
| Figure | BSX | EW |
|---|---|---|
| Last close | $48.18 | $90.77 |
| Market cap | $67B | $50B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 19.5 | 52.2 |
| 1-year return | -53% | +15% |
| 5-year return | +5.7% | -19% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Boston Scientific
Revenue of $5.4B in Q2 2026, net income $905M. Its largest reported line is Electrophysiology EP, 18% of the disclosed total.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 73% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.